By Editor , 27 October 2026
Truveta Data: 40% of Early Foundayo Users Had No Prior GLP-1 Use

United States – October 27, 2026 -- An analysis of 5,723 patients on Foundayo (oral orforglipron) found that 40.3% had no evidence of prior GLP-1 medication use, according to Truveta, which is pitching real-time "healthcare intelligence" to life science, healthcare and government teams.

Foundayo uptake runs mostly through primary care

Truveta researchers used Truveta Data to identify patients with a Foundayo prescription or medication dispense between April 1 and July 6, 2026. The drug was approved for obesity in April 2026.

By Editor , 27 October 2026
Navigation Use in Sinus Surgery Rises to 41% From 29% Since 2018

United States – October 27, 2026 -- Computer-assisted navigation was used in 41.0% of endoscopic sinus surgeries in 2026, up from 29.2% in 2018, a 40.4% relative increase, according to a Truveta Data analysis of adult patients.

Navigation used in 35.5% of 98,971 procedures over the study period

The analysis covered endoscopic sinus surgeries performed between January 1, 2018, and August 31, 2026. Visits within 90 days of a prior surgery code were counted as a single procedure. Navigation was identified through a specific add-on CPT code.

By Editor , 27 October 2026
Robotic Knee Replacement Use Triples to 36.1% as Complications Fall

United States – October 27, 2026 -- Robotic assistance in total knee arthroplasty (TKA) rose from 12.4% of procedures in 2018 to 36.1% in 2026, a 191% relative increase, according to an analysis of 362,667 procedures in Truveta Data.

Robotic assistance was used in 24.3% of all procedures in the study period, which ran from January 2018 to August 2026. Robotic-assisted cases ran longer. Median operation time was 136 minutes (IQR 116-160), against 126 minutes (IQR 109-149) without robotics.

By Editor , 27 October 2026
US Flu Hospitalizations Hit 3.5 per 1,000, Nearly 3x Prior Highs

United States – October 27, 2026 -- Influenza-associated hospitalizations reached 3.5 per 1,000 hospitalizations in the week beginning September 21, 2026, nearly three times the next-highest rate recorded at the same point in the prior six flu seasons, according to a Truveta Data analysis.

By Editor , 27 October 2026
Intensive Diuretics Boost Fluid Loss, Kidney Injury in Heart Failure

United States – October 27, 2026 -- High-dose loop diuretics combined with adjuvant therapy produced an adjusted average weight loss of 4.6 pounds in heart failure inpatients, the largest of any strategy, but also came with higher rates of acute kidney injury, according to a study in the Journal of Cardiac Failure.

By Editor , 27 October 2026
E-Bike ED Visit Rate Jumps 760% as Traditional Bike Injuries Hold Flat

United States – October 27, 2026 -- The rate of e-bike-related emergency department (ED) visits rose 760.2% between January–August 2023 and January–August 2026, while traditional bicycle visits increased only 7.9%, according to a Truveta Data analysis.

E-bike visits climbed from 1.2 to 10.1 per 100,000 people with an ED visit. The traditional bicycle rate moved from 59.4 to 64.1 per 100,000. Traditional bicycles still dominate in absolute volume: the study period recorded 63,811 traditional bicycle ED visits against 4,769 for e-bikes.

By Editor , 27 October 2026
Truveta Makes LinkedIn's Seattle Top Startups List for 4th Year

Seattle – October 27, 2026 -- Truveta has secured a place on LinkedIn's 2026 Top Startups list for Seattle, its fourth consecutive year on the ranking. The annual list covers emerging companies in the Seattle region that are attracting talent, growing quickly and building momentum.

By Editor , 27 October 2026
Truveta Genome Project Targets Largest De-Identified Exome Database

Global – October 27, 2026 -- The Truveta Genome Project aims to build the largest and most diverse de-identified database of exome-wide genomic data linked to high-fidelity clinical data ever assembled, according to a statement from a Truveta executive who joined the company earlier this year.

By Editor , 27 October 2026
CGM Users on Basal Insulin Show 45% Lower One-Year Mortality Risk

Europe – October 27, 2026 -- Continuous glucose monitoring (CGM) was associated with a 45% lower risk of death at one year among adults with type 2 diabetes on basal insulin, according to a study presented at the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting.

The analysis used Truveta Data to track nearly 28,000 adults with type 2 diabetes receiving basal insulin therapy. Researchers combined longitudinal electronic health record (EHR) and mortality data in a target trial emulation that compared CGM users with non-users.

By Editor , 27 October 2026
Truveta Genome Project Targets Tens of Millions of Participants

United States – October 27, 2026 -- Truveta aims to enroll tens of millions of consenting participants in the Truveta Genome Project. The goal is the largest and most diverse database of genotypic and phenotypic information ever assembled, according to Kristin Rand, the company's Senior Director of Genomics Partnerships.